Outcomes in critically ill patients with cancer-related complications by unknown
POSTER PRESENTATION Open Access
Outcomes in critically ill patients with cancer-related
complications
VBL Torres1*, JRL Vassalo1, N Spector1, FA Bozza2, LCP Azevedo3, JIF Salluh2, M Soares2
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Intr
The number of critically ill patients with malignancies has
increased over the past decade and acute complications of
cancer or its treatment are one of the most common
causes to ICU admission.
Objectives
Evaluate the clinical characteristics and outcomes of
patients admitted to ICUs with complications related to
cancer or its treatment in order to identify independent
risk factors associated with mortality rates.
Methods
Secondary analysis of two prospective Brazilians cohort
studies. We used logistic regression to identify variables
associated with hospital mortality.
Results
Out of 2028 patients, 456 (23%) had at least one cancer-
related complication at ICU admission. Compared to
those without complications, they had worse performance
status (PS) (57% vs 36% with PS ≥ 2, P < 0.001) and had
more active disease (5% vs 43%, P < 0.001). The median
SOFA score was higher [8 (5-11) vs 6 (4-9), P < 0.001], as
well as the need for vasopressors, mechanical ventilation
(MV) and dialysis (45% vs 34%, 70% vs 51% and 12% vs
8%, respectively) (P < 0.001 for all). The hospital length of
stay (LOS) was similar in both subgroups (P = 0.501), but
those with complications showed increased ICU mortality
(47% vs 27%, P < 0.001). The most frequent complications
were chemotherapy toxicity (5%), venous thromboembo-
lism (5%), respiratory failure by tumor (RFBT) (4%), gas-
trointestinal complications by tumor (GCBT) (3%) and
vena cava syndrome (VCS) (2%). 39/456 patients with
complications received chemotherapy and/or radiotherapy
at ICU, with no mortality difference. Adjusting for the
type of admission, hospital LOS prior to ICU and patient’s
age, the variables independently associated with hospital
mortality were: PS≥2 [OR = 2.56 (2.05-3.20), P < 0.001],
metastatic solid tumor [OR = 2.11 (1.59-2.80), P < 0.001],
high-grade hematologic malignancy [OR = 2.08 (1.36-
3.17), P = 0.001], higher SOFA score [OR = 1.16 (1.13-
1.20), P < 0.001], MV [OR = 4.08 (3.23 - 5.15), P < 0.001],
P <0.001], presence of VCS [OR = 3.72 (1.10 - 12.58), P =
0.035], GCBT [OR = 2.56 (1.29-5.09), P = 0.007] and
RFBT [OR = 1.97(1.04-3.71), P = 0.37].
Conclusions
The prognostic impact of cancer-related complications is
variable. The presence a severe acute cancer-related com-
plication per se should not guide decisions to admit a
patient to the ICU. However, patients presenting with
VCS, GCBT and RFBT had worse outcomes.
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